QT-prolonging drugs are medications that can extend the QT interval on the ECG, a measure of the heart’s electrical recovery phase. While this effect can be therapeutic in some contexts, excessive prolongation raises the risk of dangerous arrhythmias such as torsades de pointes.
Clinicians rely on up-to-date information about which drugs carry this risk, how to monitor patients, and how to adjust therapy to balance benefits against potential harm to cardiac rhythm.
| Drug Class | Examples | Typical QTc Effect (ms) | Key Clinical Note |
|---|---|---|---|
| Macrolide Antibiotics | Azithromycin, Clarithromycin | 0 to +10 | Risk higher with preexisting conditions or polypharmacy |
| Fluoroquinolones | Levofloxacin, Moxifloxacin | +5 to +20 | Moxifloxacin tends to have a larger effect than levofloxacin |
| Antipsychotics | Haloperidol, Ziprasidone | +10 to +30 | Ziprasidone requires baseline ECG and follow-up in many guidelines |
| Antiarrhythmics | Sotalol, Dofetilide | +20 to +40 | Prolongation is intended therapeutically, but excess demands dose adjustment or discontinuation |
| Antiemetics | Ondansetron, Granisetron | +5 to +15 | Ondansetron at standard doses often has modest effect; caution at higher or repeated doses |
Mechanisms of QT Prolongation
How Ion Channel Blockade Alters Repolarization
Many QT-prolonging drugs block cardiac potassium channels, delaying repolarization and lengthening the QT interval on the ECG. Drugs may also inhibit sodium or calcium currents, further shifting the balance of ionic currents during the cardiac action potential.
Risk is not only dose-dependent but also influenced by genetic variants in ion channels, electrolyte status, and concurrent medications that compete for metabolism or additive QT effects.
Clinical Risk Assessment and Monitoring
Identifying Patients Most Vulnerable to Prolongation
Baseline ECG, electrolyte review, and a careful medication list help clinicians estimate whether a drug is appropriate for a given patient. Scores such as the QT Registry criteria and credentialed EHR alerts support standardized screening.
Monitoring strategies include repeat ECGs after dose changes, avoiding multiple QT-prolonging drugs together, and correcting potassium, magnesium, and calcium when indicated.
Specific Drug Examples and Practical Guidance
Common Prescribers With Notable Effects
Selected antibiotics like azithromycin usually carry lower risk, yet azithromycin remains QT-prolonging in susceptible hosts. Respiratory fluoroquinolones such as moxifloxacin demand closer attention, especially in older adults or those with heart failure.
Among antipsychotics, ziprasidone and haloperidol are well-documented QT-prolonging agents, whereas aripiprazole and lurasidone are considered lower-risk alternatives in patients with known electrical cardiac instability.
Management Strategies and Alternatives
When QT-Prolonging Drugs Cannot Be Avoided
For necessary therapies, prescribers may select the lowest effective dose, prefer once-daily dosing to minimize peak effects, and coordinate with cardiology when feasible. Where alternatives exist, choosing a drug with a smaller mean QT effect can reduce population-level arrhythmia risk.
In complex cases, structured discontinuation of nonessential QT-prolonging agents and systematic electrolyte optimization often yield measurable safety gains without sacrificing disease control.
Key Takeaways for Safe Use
- Review baseline ECG and electrolytes before initiating known QT-prolonging drugs
- Minimize concurrent use of multiple QT-prolonging agents when possible
- Prefer lower-risk alternatives in patients with structural heart disease, older age, or genetic predisposition
- Check and correct potassium and magnesium during therapy, especially with diuretic use
- Document QT risk discussions in the medical record and reassess necessity at each follow-up
FAQ
Reader questions
Which common antibiotics are known to prolong the QT interval?
Macrolides such as azithromycin and clarithromycin, as well as fluoroquinolones like levofloxacin and moxifloxacin, are recognized QT-prolonging antibiotics that require vigilance in at-risk patients.
Do over-the-counter medications ever contribute to QT prolongation?
Certain antiemetics such as high-dose ondansetron and some herbal or supplement combinations can modestly prolong QT, so patients should disclose all nonprescription products to their clinician.
How is QT prolongation monitored in practice when starting a new medication?
Providers typically obtain a baseline ECG, review electrolytes, evaluate the cumulative QT effect of all medications, and schedule follow-up ECGs after dose escalations or when switching therapies.
What should patients do if they notice symptoms like dizziness or fainting while on a QT-prolonging drug?
They should contact their healthcare professional promptly, avoid driving or operating machinery until evaluated, and expect prompt assessment of electrolytes, ECG findings, and medication adjustments.